Article

Genetics of glaucoma can help with disease diagnosis, treatment

As the understanding of the genetics of glaucoma advances, it may one day be possible for people to obtain a cheek swab that will determine their risk of developing glaucoma.

New Orleans-As the understanding of the genetics of glaucoma advances, it may one day be possible for people to obtain a cheek swab that will determine their risk of developing glaucoma.

Specific medications could be developed that would replace a defective protein and prevent the onset of ganglion cell damage. Such things are within the realm of possibility, but they are likely to take longer to occur than when gene therapy was new some 10 years ago, said Wallace L.M. Alward, MD, professor of ophthalmology, University of Iowa.

While presenting the annual American Glaucoma Society subspecialty day lecture, Dr. Alward noted that much has been learned despite the fact that some goals are yet unrealized. For example, six known genetic loci and two genes have been identified for open-angle glaucoma, and some genetic testing is available.

However, generalized genetic screening for glaucoma is currently impractical because the genes identified so far are responsible for only a small percentage of cases. Clinical use of gene therapy is also a distant goal, Dr. Alward said.

Still, each discovery over the past decade has provided a piece of what appears to be a very big puzzle, and for the near future, a goal to strive for is to slow progression enough so that people have good vision until the time of their death, he added.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.